Document is current

Article History

Received: 18 September 2025

Accepted: 29 January 2026

First Online: 7 February 2026

Declarations

:

: This study has been approved by the Comité d’éthique à la recherche du CIUSSS de l’Estrie–CHUS (Project No. 2024–5200). The ethics committee reviewed and approved all study-related materials, including the informed consent forms, questionnaires, recruitment documents, funding sources, and the project’s scientific justification. Participants will receive an information and consent form written in plain language, available in both English and French. This document will be sent via email prior to visit 1, allowing participants sufficient time to review the study details. The research team will be available by email or phone to address any questions. Informed consent will be reconfirmed prior to each intervention, and participants will retain the right to withdraw from the study at any time without providing a reason.

: Not applicable.

: ELM received honoraria for a one-time consulting contract with Sun Pharma in 2021, prior to the design of this study. He also received honoraria from CooperVision in 2024, and from Johnson and Johnson in 2025 as well as funding support from the Canadian Optometric Education Trust Fund, the American Academy of Optometry Foundation, and CANTRAIN in previous years. LM has received honoraria and/or research funding from Bausch and Lomb, Johnson and Johnson, Cooper Vision, Sun Pharma, Thea, and EssilorLuxottica in the past years. MFD has no competing interest. PB has no competing interest.